Sun Pharmaceutical Gains Ground Following Release of Generic Cancer Drug

Sun Pharmaceutical rose the most in 14 months after the U.S. approved the company’s generic version of Johnson & Johnson’s cancer drug Doxil (doxorubicin HCl liposome injection).
NJ Star-Ledger